Bioaffinity Technologies revenue was $9.36M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $2.2M, down 6.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BIAF annual revenue was $9.4M, with 269.7% growth year-over-year.
BIAF past revenue growth
How has BIAF's revenue growth performed historically?
Bioaffinity Technologies (NASDAQ: BIAF) reported Q4 2024 revenue of $2.21 million up 0.26% year over year. In the same quarter last year, Bioaffinity Technologies's revenue was $2.21 million.
What was Bioaffinity Technologies's revenue in 2024?
Bioaffinity Technologies's annual revenue for the twelve months ending Dec 31, 2024 was $9.36 million, a 269.68% increase year over year.
How much does Bioaffinity Technologies make in a day?
Based on Bioaffinity Technologies annual revenue for the past four years, BIAF makes an average of $8,150.22 per day.
What was Bioaffinity Technologies's annual revenue growth in the past year?
As of Q2 2025, Bioaffinity Technologies's revenue has grown 269.68% year over year. This is 265.72 percentage points higher than the US Diagnostics & Research industry revenue growth rate of 3.95%. Bioaffinity Technologies's revenue in the past year totaled $9.36 million.
How much does Bioaffinity Technologies make in a year?
Bioaffinity Technologies's revenue by year for the past four years is:
Bioaffinity Technologies's revenue for the twelve months ending Dec 31, 2024 was $9.36 million, a 269.68% increase year over year.
Bioaffinity Technologies's annual revenue for Dec 31, 2023 was $2.53 million, a 52,627.44% increase from 2022.
Bioaffinity Technologies's annual revenue for 2022 was $4.80 thousand, a Infinity% increase from 2021.
Bioaffinity Technologies's annual revenue for 2021 was $0.00, a N/A decrease from 2020.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.